These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

377 related items for PubMed ID: 18265413

  • 41. Defective lysosomal arginine transport in juvenile Batten disease.
    Ramirez-Montealegre D, Pearce DA.
    Hum Mol Genet; 2005 Dec 01; 14(23):3759-73. PubMed ID: 16251196
    [Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44. Distinct early molecular responses to mutations causing vLINCL and JNCL presage ATP synthase subunit C accumulation in cerebellar cells.
    Cao Y, Staropoli JF, Biswas S, Espinola JA, MacDonald ME, Lee JM, Cotman SL.
    PLoS One; 2011 Feb 17; 6(2):e17118. PubMed ID: 21359198
    [Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46. A mouse model for Finnish variant late infantile neuronal ceroid lipofuscinosis, CLN5, reveals neuropathology associated with early aging.
    Kopra O, Vesa J, von Schantz C, Manninen T, Minye H, Fabritius AL, Rapola J, van Diggelen OP, Saarela J, Jalanko A, Peltonen L.
    Hum Mol Genet; 2004 Dec 01; 13(23):2893-906. PubMed ID: 15459177
    [Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50. CLN3p impacts galactosylceramide transport, raft morphology, and lipid content.
    Rusyn E, Mousallem T, Persaud-Sawin DA, Miller S, Boustany RM.
    Pediatr Res; 2008 Jun 01; 63(6):625-31. PubMed ID: 18317235
    [Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52. CLN3L, a novel protein related to the Batten disease protein, is overexpressed in Cln3-/- mice and in Batten disease.
    Narayan SB, Pastor JV, Mitchison HM, Bennett MJ.
    Brain; 2004 Aug 01; 127(Pt 8):1748-54. PubMed ID: 15240430
    [Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54. Neuronal vulnerability of CLN3 deletion to calcium-induced cytotoxicity is mediated by calsenilin.
    Chang JW, Choi H, Kim HJ, Jo DG, Jeon YJ, Noh JY, Park WJ, Jung YK.
    Hum Mol Genet; 2007 Feb 01; 16(3):317-26. PubMed ID: 17189291
    [Abstract] [Full Text] [Related]

  • 55. Osmoregulation of ceroid neuronal lipofuscinosis type 3 in the renal medulla.
    Stein CS, Yancey PH, Martins I, Sigmund RD, Stokes JB, Davidson BL.
    Am J Physiol Cell Physiol; 2010 Jun 01; 298(6):C1388-400. PubMed ID: 20219947
    [Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58. Tissue expression and subcellular localization of CLN3, the Batten disease protein.
    Margraf LR, Boriack RL, Routheut AA, Cuppen I, Alhilali L, Bennett CJ, Bennett MJ.
    Mol Genet Metab; 1999 Apr 01; 66(4):283-9. PubMed ID: 10191116
    [Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60. Gene Therapy Targeting the Inner Retina Rescues the Retinal Phenotype in a Mouse Model of CLN3 Batten Disease.
    Kleine Holthaus SM, Aristorena M, Maswood R, Semenyuk O, Hoke J, Hare A, Smith AJ, Mole SE, Ali RR.
    Hum Gene Ther; 2020 Jul 01; 31(13-14):709-718. PubMed ID: 32578444
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.